DecisionDx-UM

Last updated

DecisionDx-UM is a prognostic test that accurately determines the metastatic risk associated with ocular melanoma tumors of the eye. Ocular melanoma is a term commonly used to describe tumors of the uveal tract such as uveal melanoma, choroidal melanoma, ciliary body melanoma, and iris melanoma. The DecisionDx-UM test was clinically validated on these tumors of the uveal tract. DecisionDx-UM assesses the gene expression profile (GEP) of a subset of genes which are differentially expressed in primary tumor cells compared to cells that have undergone transformation to a metastatic phenotype.

Contents

The test classifies tumors as:

Also referred to as the gene expression profile, the test has been directly compared to all other clinical and pathological factors, such as chromosome 3 status (monosomy 3), cytopathology and tumor size and the DecisionDx-UM test was shown to be more accurate than these other factors. [2] The DecisionDx-UM test has become standard of care in the majority of ocular oncology centers in the U.S. and is recommended by the American Joint Committee on Cancer (AJCC). The AJCC recommends this testing for all patients with a diagnosis of uveal melanoma as the results are ‘clinically significant’. Accurate results are achieved using both fine needle aspirate biopsies (FNAB) or formalin fixed, paraffin embedded (FFPE) tumor tissue. The prognostic information provided by DecisionDx-UM helps physicians and their patients make individualized decisions about the surveillance and therapeutic options that are most appropriate. The DecisionDx-UM test was exclusively licensed from Washington University in St. Louis and is only available through Castle Biosciences, Incorporated.

Uveal Melanoma

While rare, uveal melanoma (ocular melanoma) is the most common form of eye cancer and the second most common form of melanoma. Uveal melanoma tumors arise in the uveal tract of the eye which includes the iris, ciliary body, and choroid. Treatment for the primary eye tumor consists of eye-sparing therapy (plaque radiotherapy or proton beam irradiation) or eye removal (enucleation). Both are highly effective with ‘cure’ rates above 90%. However, as has been well documented in multiple publications including the Collaborative Ocular Melanoma Study (COMS), in nearly 50% of patients the melanoma has likely already metastasized by the time the primary eye tumor has been diagnosed and treated. [3] [4] The majority of these metastases are microscopic and clinically undetectable at the time of primary tumor diagnosis. [5] Unfortunately, many of the current diagnostic techniques (including imaging and liver function tests) are not able to accurately detect micrometastases until tumor nodules have grown considerably, and likely become resistant to therapy. [6] [7]

The lack of accurate prognostic tests to identify which patients are at risk of developing clinically overt metastatic disease has been a significant issue in the management of individual patients with uveal melanoma. Without accurate measures of individual metastatic risk, it is impossible to identify which patients are at high risk for clinical metastasis, which can then lead to either over or under-treatment of any given patient. The DecisionDx-UM test was developed to provide improved individual metastatic risk assessment which allows for more appropriate surveillance and treatment planning.

DecisionDx-UM GEP Assay

Discovery

The gene expression profile measured by DecisionDx-UM was discovered in the laboratory of J. William Harbour at Washington University in St. Louis. [8] [9] The application of microarray analysis to primary untreated uveal melanomas revealed that the tumors clustered into two discreet groups based upon their expression profiles. [8] Filtering of the differentially expressed gene set led to the identification of a set of genes able to discriminate between Class 1 and Class 2 tumors.

In subsequent experiments, Dr. Harbour's group assembled microarray information from a larger subset of uveal melanoma tumor samples, and were able to identify candidate discriminatory genes for further analysis. [9] The genetic expression profiles of those discriminating genes were verified in uveal melanoma tumors using quantitative polymerase chain reaction (qPCR) methods, and predictive modeling was performed to identify an optimum set of genes able to accurately predict metastatic risk and report class assignments. [9] [10] The final assay evaluated 12 discriminating genes and 3 control genes to determine Class 1 (low risk) and Class 2 (high risk) tumors, and was validated in a 609 patient multicenter study that included FNAB and FFPE samples. [9]

Prognostic Accuracy

The current DecisionDx-UM platform was clinically validated in the COOG study, which included 514 patients with UM treated at 12 ocular oncology centers in the United States between 1998 and 2010. [1] The report provides data showing that DecisionDx-UM has a high technical success rate (>95%).

Clinical Technical Success

Since the initial offering of DecisionDx-UM in December 2009, more than 800 clinical orders have been received for analysis by Castle Biosciences from over 55 ocular oncology centers across the U.S. Technical success and class determination was achieved for 96.2% of the samples. [11] Most of the failures were due to improper biopsy collection and/or handling. Tumor biopsy collection is critical for the successful reporting of metastatic risk Class assignment following DecisionDx-UM testing.

DecisionDx-UM Ordering and Reporting

Castle Biosciences, Incorporated only accepts service orders for DecisionDx-UM from licensed physicians (most commonly ocular oncologists, ophthalmologists, or retina specialists) who care for patients diagnosed with uveal melanoma. Physicians who are first time customers must contact Castle's for information and to establish an account. Sample submission requires submission of a DecisionDx-UM Requisition Form to be completed and faxed to Castle. FNAB specimens require use of a specimen collection kit, provided by Castle, to stabilize the sample and reduce the chance of technical failure. This kit must be received by the ordering physician prior to sample collection. Castle staff is available to assist with logistics concerning sample collection and shipping.

Castle provides a report to the ordering physician that will classify the tumor as Class 1A, Class 1B, or Class 2. The report will also describe the statistics associated with the classification, and provide a discriminant value that reflects the confidence regarding the classification. The information provided in the report from Castle identifies how likely a tumor is to metastasize (spread) with this risk being categorized as low (Class 1A), intermediate (Class 1B), or high (Class 2).

Other UM Metastasis Prognostic Factors

Histopathologic Factors and Imaging Techniques

Historically there are several clinical and pathologic features that have been statically associated with metastasis. [12] [13] Tumor size, tumor location, patient age and vascular structure have all been reported to correlate with metastatic onset and patient survival. [2] [12] [13] [14] While generalities regarding the UM patient population at large can be made based on these factors, none, alone or collectively, has demonstrated predictive accuracy with regard to metastatic activity.

Imaging techniques used to detect metastatic activity also have limitations. Systemic metastases are detected by Positron Emission Tomography (PET) imaging at the time of the original diagnosis in less than 4% of UM patients [6] Magnetic Resonance Imaging (MRI) has recently been reported more sensitive than PET for identifying metastasis from choroidal melanoma, but MRI requires tumor mass greater than 5mm in size. [15] Thus, current imaging technology lacks the sensitivity for detecting micrometastases that may be present at the time of primary diagnosis of uveal melanoma.

Genetic Factors

Genetic analysis techniques have led to the identification of chromosomal abnormalities associated with metastatic tumor progression in uveal melanoma. Loss of heterozygosity, loss of entire alleles from chromosomes, partial chromosomal addition and chromosomal deletion and single nucleotide polymorphisms (SNP) have been associated with uveal melanoma metastatic lesions. [16] [17] [18] [19] [20] In particular, chromosomes 1, 3, 6 and 8 have been extensively studied for their association with shorter survival time and development of metastatic disease. [17] [19] [20] [21] [22] [23] [24]

While genetic aberrations in chromosomes 1, 6 and 8 have not independently been able to predict disease progression, cytogenetic profiling of chromosome 3 has uncovered an important genetic region highly associated with metastatic onset in uveal melanoma patients. [16] [23] Chromosome 3 abnormalities have been analyzed using multiple techniques, including fluorescence in situ hybridization (FISH), chromosomal in situ hybridization (CISH), array comparative genomic hybridization (aCGH), SNP, multiplex ligation-dependent probe amplification (MLPA), and microsatellite analysis. [16] [21] [25] [26] [27] [28]

Despite a wealth of data that has identified the association of chromosome 3 mutation with UM metastasis, the clinical application of this data has yet to be realized. [29] Reasons for the uncertainty of chromosome 3 clinical use include:

Furthermore, unlike the DecisionDx-UM test, there are no published, peer-reviewed studies that demonstrate clinical validation in an independent set of patients.

Castle Biosciences, Incorporated

Castle Biosciences, Inc.
Nasdaq:  CSTL

Castle Biosciences, Incorporated is a molecular diagnostics company that develops diagnostic and prognostic assays for rare cancers. Castle's mission is to serve individuals afflicted with rare cancers by offering accurate prognostic tests which provide information for making critical decisions regarding an individual's surveillance and treatment regimens. In addition to DecisionDx-UM, Castle offers prognostic tests for melanoma (DecisionDx-Melanoma) and squamous cell carcinoma (DecisionDx-SCC). Castle is based in Friendswood, TX, and has operations in Phoenix, AZ.

Related Research Articles

<span class="mw-page-title-main">Retinoblastoma</span> Medical condition

Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina, the light-detecting tissue of the eye. It is the most common primary malignant intraocular cancer in children, and it is almost exclusively found in young children.

In medicine, Breslow's depth was used as a prognostic factor in melanoma of the skin. It is a description of how deeply tumor cells have invaded. Currently, the standard Breslow's depth has been replaced by the AJCC depth, in the AJCC staging system of melanoma. Originally, Breslow's depth was divided into 5 stages.

<span class="mw-page-title-main">Melanoma</span> Cancer originating in melanocytes

Melanoma, also redundantly known as malignant melanoma, is a type of cancer that develops from the pigment-producing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men, they most commonly occur on the back. About 25% of melanomas develop from moles. Changes in a mole that can indicate melanoma include an increase in size, irregular edges, change in color, itchiness, or skin breakdown.

<span class="mw-page-title-main">Uveal melanoma</span> Type of eye cancer

Uveal melanoma is a type of eye cancer in the uvea of the eye. It is traditionally classed as originating in the iris, choroid, and ciliary body, but can also be divided into class I and class II. Symptoms include blurred vision, loss of vision or photopsia, but there may be no symptoms.

<span class="mw-page-title-main">Eye neoplasm</span> Medical condition

Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). Eye cancers can be primary or metastatic cancer. The two most common cancers that spread to the eye from another organ are breast cancer and lung cancer. Other less common sites of origin include the prostate, kidney, thyroid, skin, colon and blood or bone marrow.

Ciliary body melanoma is a type of cancer arising from the coloured part (uvea) of the eye.

<span class="mw-page-title-main">Ipilimumab</span> Pharmaceutical drug

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

<span class="mw-page-title-main">Tumor-infiltrating lymphocytes</span>

Tumor-infiltrating lymphocytes (TIL) are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis.

<span class="mw-page-title-main">Bi-specific T-cell engager</span>

Bi-specific T-cell engagers (BiTEs) are a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells' cytotoxic activity, against cancer cells. BiTE is a registered trademark of Micromet AG.

Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.

Virtual karyotype is the digital information reflecting a karyotype, resulting from the analysis of short sequences of DNA from specific loci all over the genome, which are isolated and enumerated. It detects genomic copy number variations at a higher resolution for level than conventional karyotyping or chromosome-based comparative genomic hybridization (CGH). The main methods used for creating virtual karyotypes are array-comparative genomic hybridization and SNP arrays.

Paul T. Finger, MD, FACS, is an ophthalmologist in New York, New York, specializing in ocular oncology. Finger is a Clinical Professor of Ophthalmology at the New York University School of Medicine in New York City, New York. He is also the director of The New York Eye Cancer Center and Ocular Tumor Services at The New York Eye and Ear Infirmary of Mt. Sinai. He consults for Northwell Health Complex of affiliated Hospitals including Manhattan Eye, Ear and Throat Hospital and NYU School of Medicine. He is Chair of the Ophthalmic Oncology Task Force for the American Joint Committee on Cancer (AJCC), wrote the eye cancer staging systems section for the Union International for Cancer Control (UICC). As Chair, he brought together an OOTF to develop consensus eye plaque radiation guidelines for The American Brachytherapy Society - American Association of Physicists in Medicine. Dr. Finger was the first the only ophthalmologist asked to serve on the 2012 American Association of Physicists in Medicine’s Task Group-129 that produced both dosimetry and quality assurance standards for plaque brachytherapy. As of 2021, Dr. Finger has authored over 335 peer-review scientific articles, 2 books, 54 book chapters and 2 web sites.

<span class="mw-page-title-main">Brain metastasis</span> Cancer that has metastasized (spread) to the brain from another location in the body

A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, as primary tumors that originate in the brain are less common. The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain metastases can occur in patients months or even years after their original cancer is treated. Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years after the diagnosis.

Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

<span class="mw-page-title-main">Cancer biomarker</span> Substance or process that is indicative of the presence of cancer in the body

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.

<span class="mw-page-title-main">J. William Harbour</span> American ophthalmologist and researcher

J. William Harbour is an American ophthalmologist, ocular oncologist and cancer researcher. He is Chair of the Department of Ophthalmology at the University of Texas Southwestern Medical Center in Dallas. He previously served as the vice chair and director of ocular oncology at the Bascom Palmer Eye Institute and associate director for basic science at the Sylvester Comprehensive Cancer Center of the University of Miami's Miller School of Medicine.

The Immunologic Constant of Rejection (ICR), is a notion introduced by biologists to group a shared set of genes expressed in tissue destructive-pathogenic conditions like cancer and infection, along a diverse set of physiological circumstances of tissue damage or organ failure, including autoimmune disease or allograft rejection. The identification of shared mechanisms and phenotypes by distinct immune pathologies, marked as a hallmarks or biomarkers, aids in the identification of novel treatment options, without necessarily assessing patients phenomenologies individually.

<span class="mw-page-title-main">Sarah Coupland</span> Australian clinical pathologist

Sarah Coupland is an Australian-born pathologist and professor who is the George Holt Chair in Pathology at the University of Liverpool. Coupland is an active clinical scientist whose research focuses on the molecular genetics of cancers, with particular interests in uveal melanoma, conjunctival melanoma, intraocular and ocular adnexal lymphomas and CNS lymphoma. Coupland is also an NHS Honorary Consultant Histopathologist at the Royal Liverpool University Hospital. Since 2006, Coupland has been head of the Liverpool Ocular Oncology Research Group; from which she runs a multidisciplinary oncology research group focussing on Uveal melanoma, based in the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool. Her research laboratory is currently located in the Institute of Translational Medicine From April 2014 to December 2019, Coupland was also Director of the North West Cancer Research Centre, @UoL. In both 2019 and 2020, Coupland was included on the 'Pathology Powerlist' on The Pathologist website.

<span class="mw-page-title-main">Choroidal nevus</span> Medical condition

Choroidal nevus is a type of eye neoplasm that is classified under choroidal tumors as a type of benign (non-cancerous) melanocytic tumor. A choroidal nevus can be described as an unambiguous pigmented blue or green-gray choroidal lesion, found at the front of the eye, around the iris, or the rear end of the eye.

References

  1. 1 2 Harbour, J.W., Retina Times 2011;29: 36-7.
  2. 1 2 3 Worley, L.A., et al., Clinical Cancer Research, 2007. 13(5): p. 1466-71.
  3. ↑ Archives of Ophthalmology, 2006. 124(12): p. 1684-93.
  4. ↑ Diener-West, M., et al., Archives of Ophthalmology, 2001. 119(7): p. 969-82.
  5. ↑ Harbour, J.W., Clinical overview of uveal melanoma:introduction to tumors of the eye., ed. D.M. Albert, Polans, A.2003: Marcel Dekker. 1-18.
  6. 1 2 Finger, P.T., et al., The British Journal of Ophthalmology, 2005. 89(10): p. 1270-4.
  7. ↑ Kurli, M., et al., American Journal of Ophthalmology, 2005. 140(2): p. 193-9.
  8. 1 2 Onken, M.D., et al., Cancer research, 2004. 64(20): p. 7205-9.
  9. 1 2 3 4 Onken, M.D., et al., The Journal of molecular diagnostics : JMD, 2010. 12(4): p. 461-8.
  10. ↑ Onken, M.D., et al., The Journal of molecular diagnostics : JMD, 2006. 8(5): p. 567-73.
  11. ↑ Bergstrom, C.S., Hovland, P. G., Stone, J. F., Oelschlager, K., and Cook, R. W., 2011.
  12. 1 2 Augsburger, J.J. and J.W. Gamel, Cancer, 1990. 66(7): p. 1596-600.
  13. 1 2 McLean, I.W., K.S. Keefe, and M.N. Burnier, Ophthalmology, 1997. 104(5): p. 777-80.
  14. ↑ Foss, A.J., et al., Cancer research, 1996. 56(13): p. 2900-3.
  15. ↑ Servois, V., et al., European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2010. 36(2): p. 189-94.
  16. 1 2 3 Harbour, J.W., et al., Science, 2010. 330(6009): p. 1410-3.
  17. 1 2 Kilic, E., et al., Investigative ophthalmology & visual science, 2006. 47(9): p. 3703-7.
  18. ↑ Onken, M.D., L.A. Worley, and J.W. Harbour, Clinical Cancer Research, 2008. 14(12): p. 3737-45.
  19. 1 2 Prescher, G., N. Bornfeld, and R. Becher, Journal of the National Cancer Institute, 1990. 82(22): p. 1765-9.
  20. 1 2 Sisley, K., et al., Genes, Chromosomes & Cancer, 1990. 2(3): p. 205-9.
  21. 1 2 Damato, B., J.A. Dopierala, and S.E. Coupland, Clinical Cancer Research, 2010. 16(24): p. 6083-92.
  22. ↑ Sisley, K., et al., Genes, Chromosomes & Cancer, 1997. 19(1): p. 22-8.
  23. 1 2 Prescher, G., et al., Lancet, 1996. 347(9010): p. 1222-5.
  24. ↑ Singh, A.D., et al., Archives of Pathology & Laboratory Medicine, 2009. 133(8): p. 1223-7.
  25. ↑ Naus, N.C., et al., Clinical Cancer Research, 2002. 8(2): p. 534-9.
  26. 1 2 Onken, M.D., et al., Clinical Cancer Research, 2007. 13(10): p. 2923-7.
  27. ↑ Sandinha, M.T., M.A. Farquharson, and F. Roberts, The British Journal of Ophthalmology, 2004. 88(12): p. 1527-32.
  28. ↑ Tschentscher, F., et al., Cancer genetics and cytogenetics, 2000. 122(1): p. 13-7.
  29. 1 2 Damato, B. and S.E. Coupland, Archives of Ophthalmology, 2009. 127(4): p. 423-9.
  30. ↑ Maat, W., et al., Archives of Pathology & Laboratory Medicine, 2007. 131(1): p. 91-6.
  31. ↑ Mensink, H.W., et al., Investigative ophthalmology & visual science, 2009. 50(2): p. 500-4.
  32. ↑ Midena, E., et al., European journal of ophthalmology, 2006. 16(3): p. 422-5.
  33. ↑ Shields, C.L., et al., Transactions of the American Ophthalmological Society, 2007. 105: p. 43-52; discussion 52-3.
  34. ↑ Young, T.A., et al., Ophthalmology, 2007. 114(1): p. 142-6.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.